KMTS · XBRL financial data
Kestra Medical Technologies financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (KMTS's year ends in late April)
| In thousands of dollars | Apr 30, 2025 | Apr 30, 2026 |
|---|---|---|
| Revenue from contracts with customers | 59,815 | 95,126 |
| Cost of goods and services sold | 35,605 | 46,263 |
| Gross profit | 24,210 | 48,863 |
| Research and development | 15,652 | 19,484 |
| Selling, general and administrative | 114,936 | 164,120 |
| Total operating expenses | 130,588 | 183,604 |
| Operating income (loss) | (106,378) | (134,741) |
| Interest income | 3,199 | 8,351 |
| Interest expense | 7,734 | 7,546 |
| Other income (expense) | (2,766) | 2,618 |
| Income tax expense (benefit) | 135 | 294 |
| Net income (loss) | (113,814) | (131,612) |
| Earnings per share, basic USD per share | (5.13) | (2.43) |
| Earnings per share, diluted USD per share | (5.13) | (2.43) |
| Weighted average shares, basic thousands of shares | 24,584 | 54,185 |
| Weighted average shares, diluted thousands of shares | 24,584 | 54,185 |
Balance sheet
CSVFiscal years (KMTS's year ends in late April)
| In thousands of dollars | Apr 30, 2025 | Apr 30, 2026 |
|---|---|---|
| Cash and cash equivalents | 237,595 | 99,710 |
| Short-term investments | — | 96,724 |
| Prepaid and other current assets | 3,080 | 4,677 |
| Total current assets | 255,328 | 222,359 |
| Property and equipment, net | 34,830 | 59,090 |
| Right-of-use asset | 2,078 | 3,364 |
| Total assets | 295,744 | 358,465 |
| Accounts payable | 23,961 | 27,295 |
| Accrued liabilities | 13,829 | 23,046 |
| Total current liabilities | 37,977 | 50,372 |
| Long-term debt | 41,098 | 42,649 |
| Lease liability, non-current | 3,026 | 4,111 |
| Total liabilities | 90,338 | 98,807 |
| Accumulated deficit | (520,249) | (651,861) |
| Total liabilities and equity | 295,744 | 358,465 |
| Common shares outstanding (cover page) thousands of shares | 51,349 | 58,602 |
Cash flows
CSVFiscal years (KMTS's year ends in late April)
| In thousands of dollars | Apr 30, 2025 | Apr 30, 2026 |
|---|---|---|
| Net income (loss) | (113,814) | (131,612) |
| Stock-based compensation | 24,270 | 33,644 |
| Depreciation and amortization | 7,968 | 8,709 |
| Net cash from operating activities | (77,608) | (81,703) |
| Purchases of property and equipment | 22,936 | 34,892 |
| Net cash from investing activities | (23,308) | (203,277) |
| Proceeds from issuing common stock | 215,789 | 149,291 |
| Net cash from financing activities | 330,262 | 147,095 |
| Net change in cash | 229,346 | (137,885) |
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Kestra Medical Technologies | 68,558 | 30,971 | (32,295) | 59.6M | 4.9 quarters | 10-QJul 31, 2026 |
| Beta Bionics | 81,551 | 35,505 | (12,287)* | 54.4M | 13.0 quarters | 10-QSep 30, 2026 |
| Cadre Holdings | 53,984 | 207,126 | 22,131* | 42.8M | — | 10-QJun 30, 2026 |
| Avanos Medical | 65,600 | 182,200 | (12,300) | 46.8M | 5.3 quarters | 10-QMar 31, 2026 |
| Mimedx Group | 120,791 | 62,283 | 3,919* | 145.9M | — | 10-QSep 30, 2026 |
| Embecta | 214,700 | 271,700 | 41,800* | 56.7M | — | 10-QJun 30, 2026 |
| Iradimed | 63,288 | 24,203 | 6,997* | 12.8M | — | 10-QSep 30, 2026 |
| SI-BONE | 33,128 | 56,010 | 777* | 44.8M | — | 10-QJun 30, 2026 |
| Biolife Solutions | 23,997 | not reported | 6,348* | 48.9M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.